HELX

Franklin Genomic Advancements ETF · BATS

Category Equity
Expense Ratio 0.5%
Listing Date Feb 27, 2020
Volume 701.0
Market Cap (AUM) $11.25M

Performance

+1.69%

-2.98%

-5.37%

+5.72%

+5.51%

YTD

+16.44%

Top Holdings

Name
Symbol
%Assets
Medpace Holdings, Inc.MEDP6.95%
Vertex Pharmaceuticals IncorporatedVRTX5.51%
Regeneron Pharmaceuticals, Inc.REGN5.14%
Danaher CorporationDHR5.11%
Thermo Fisher Scientific Inc.TMO4.75%
Eli Lilly and CompanyLLY4.69%
Krystal Biotech, Inc.KRYS4.36%
Natera, Inc.NTRA3.49%
Astrazeneca PLC Sponsored ADRAZN2.74%
SAMSUNG BIOLOGICS Co., Ltd.2079402.73%

Advanced Technical Analysis

Technical Analysis of HELX 2024-10-17

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 43 indicating a slightly bearish outlook, while the Oscillators Score at 50 suggests indecision in momentum. The Technical Score of 46 further reinforces this neutral stance, indicating that the stock is currently lacking strong bullish or bearish signals.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Recent News & Updates

2021-07-15 23:19
Blockchain will be hugely disruptive to the finance industry: Jenny Johnson(Yahoo Finance)
2021-01-13 20:15
Franklin Adds To Thematic ETF Line(Yahoo Finance)
2020-10-04 20:00
Franklin Templeton Gives Matt Moberg Three New Funds To Run(Investors)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.